SCHEMBL5137007

SCHEMBL5137007

CCCCN(Cc1ccc(OC)c(OC)c1OC)Cc1c(-c2ccc(OC)cc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.38
DRD3 P35462 4/20 0.38
GAA P10253 3/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
TSHR P16473 2/20 0.38
LMNA P02545 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
C5AR1 P21730 1/20 0.38
ATP4A P20648 2/20 0.37
ATP4B P51164 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.36
TP53 P04637 1/20 0.36
BCHE P06276 5/20 0.36
HSD17B10 Q99714 1/20 0.36
POLB P06746 1/20 0.36
PDE4B Q07343 1/20 0.35
CASR P41180 1/20 0.35
GNRHR P30968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136445 0.94 DRD2 (0.38) DRD2DRD3GAAKDM4EALDH1A1
SCHEMBL5135915 0.93 BCHE (0.41) DRD2DRD3GAAKDM4EALDH1A1
SCHEMBL5070121 0.93 SMN1; SMN2 (0.41) GAAKDM4EALDH1A1TSHRC5AR1
SCHEMBL5135989 0.92 SMN1; SMN2 (0.39) DRD2DRD3GAAKDM4EALDH1A1
SCHEMBL5137330 0.89 BCHE (0.43) C5AR1BCHECASR
SCHEMBL5135241 0.89 C5AR1 (0.42) DRD2DRD3GAAKDM4EALDH1A1
SCHEMBL5134702 0.88 ALDH1A1 (0.42) DRD2DRD3GAAKDM4EALDH1A1
SCHEMBL5138090 0.87 TP53 (0.40) GAAKDM4EALDH1A1TSHRC5AR1
SCHEMBL5072348 0.87 POLB (0.37) DRD2DRD3GAAKDM4EALDH1A1
SCHEMBL5137973 0.87 TP53 (0.41) DRD2DRD3GAATSHRC5AR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed